elafibranor 120mg + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Alcoholic Fatty Liver
Conditions
Non-Alcoholic Fatty Liver
Trial Timeline
Aug 16, 2019 → Jul 14, 2020
NCT ID
NCT03953456About elafibranor 120mg + Placebo
elafibranor 120mg + Placebo is a phase 2 stage product being developed by Genfit for Non-Alcoholic Fatty Liver. The current trial status is terminated. This product is registered under clinical trial identifier NCT03953456. Target conditions include Non-Alcoholic Fatty Liver.
What happened to similar drugs?
0 of 4 similar drugs in Non-Alcoholic Fatty Liver were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03953456 | Phase 2 | Terminated |
Competing Products
20 competing products in Non-Alcoholic Fatty Liver